Oral Anticoagulants for Nonvalvular Atrial Fibrillation in Patients With High Risk of Gastrointestinal Bleeding-Reference-Cited by-同舟云学术

Oral Anticoagulants for Nonvalvular Atrial Fibrillation in Patients With High Risk of Gastrointestinal Bleeding

Published:2021-08-16 Issue:8 Volume:4 Page:e2120064
ISSN:2574-3805
Container-title:JAMA Network Open
language:en
Short-container-title:JAMA Netw Open

Author:

Lip Gregory Y. H.¹²³⁴,Keshishian Allison V.⁵⁶,Zhang Yan⁷,Kang Amiee⁷,Dhamane Amol D.⁷,Luo Xuemei⁸,Klem Christian⁷,Ferri Mauricio⁷,Jiang Jenny⁷,Yuce Huseyin⁶,Deitelzweig Steven³⁴

Affiliation:

1. Liverpool Centre for Cardiovascular Science, University of Liverpool and Liverpool Heart & Chest Hospital, Liverpool, United Kingdom

2. Aalborg Thrombosis Research Unit, Department of Clinical Medicine, Aalborg University, Aalborg, Denmark

3. Ochsner Clinic Foundation, Department of Hospital Medicine, New Orleans, Louisiana

4. The University of Queensland School of Medicine, Ochsner Clinical School, New Orleans, Louisiana

5. STATinMED Research, Ann Arbor, Michigan

6. New York City College of Technology, City University of New York

7. Bristol Myers Squibb Company, Lawrenceville, New Jersey

8. Pfizer, Inc., Groton, Connecticut

Publisher

American Medical Association (AMA)

Subject

General Medicine

Link

https://jamanetwork.com/journals/jamanetworkopen/articlepdf/2783045/lip_2021_oi_210593_1631547210.69185.pdf

Reference21 articles.

1. Direct comparative effectiveness and safety between non–vitamin K antagonist oral anticoagulants for stroke prevention in nonvalvular atrial fibrillation: a systematic review and meta-analysis of observational studies.;Li;Eur J Epidemiol,2019

2. Stroke prevention in atrial fibrillation: past, present and future—comparing the guidelines and practical decision-making.;Lip;Thromb Haemost,2017

3. Gastrointestinal bleeding in patients on novel oral anticoagulants: risk, prevention and management.;Cheung;World J Gastroenterol,2017

4. Comparative risk of gastrointestinal bleeding with dabigatran, rivaroxaban, and warfarin: population based cohort study.;Abraham;BMJ,2015

5. Major bleeding risk during anticoagulation with warfarin, dabigatran, apixaban, or rivaroxaban in patients with nonvalvular atrial fibrillation.;Adeboyeje;J Manag Care Spec Pharm,2017

Cited by 32 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Evaluation of the Hemocompatibility of the Direct Oral Anticoagulant Apixaban in Left Ventricular Assist Devices;JACC: Heart Failure;2024-09

2. Low-Dose Direct Oral Anticoagulation vs Dual Antiplatelet Therapy After Left Atrial Appendage Occlusion;JAMA Cardiology;2024-08-07

3. Apixaban vs rivaroxaban in patients with atrial fibrillation at high or low bleeding risk: A population-based cohort study;Heart Rhythm;2024-08

4. To treat or not to treat: a comparative effectiveness analysis of oral anticoagulant outcomes among U.S. nursing home residents with atrial fibrillation;BMC Geriatrics;2024-07-19

5. Adverse Events Requiring Hospitalization Following Catheter Ablation for Atrial Fibrillation in Heart Failure with versus without Systolic Dysfunction;Journal of Cardiovascular Development and Disease;2024-01-23